IL13RA2 and neoplasm: Hegde et al. created CAR-T cells expressing a HER2-binding scFv and an IL-13Rα2-binding IL-13 mutein, which could efficiently recognize and kill either HER2 or IL-13Rα2 positive tumor cells (62).